I
Tepkinly is licensed
for 3L+ DLBCL
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly has a conditional marketing authorisation
- further data awaited.
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
Tepkinly is licensed for 3L+ DLBCL
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly has a conditional marketing authorisation
- further data awaited.
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
Downloadable Resources
Tepkinly dosing and administration guide
A digital guide to dosing and administration of Tepkinly. The guide also provides instructions on how to prepare and store Tepkinly, along with important safety information.
Tepkinly patient information booklet
A booklet for you to download and pass onto your patients who have been prescribed Tepkinly. It contains information that can be referred to throughout treatment, including understanding the Tepkinly treatment routine and possible side effects. This is for use in conjunction with the patient information leaflet.
Tepkinly Preparation and Administration
A guide to the dilution and preparation of the priming (0.16mg), intermediate (0.8mg) doses, and the preparation of the full dose (48mg) of Tepkinly for subcutaneous administration. View the video for a full run through on storage, handling and preparation of Tepkinly, indicated as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly Mode of Action animation
The Tepkinly mechanism of action is explained in this video which shows how by binding simultaneously to CD3 on T cells and CD20 on B cells, epcoritamab forms an immune synapse – inducing cytokine release and T-cell–mediated killing of malignant CD20-expressing cells.1
Tepkinly and the bispecific innovation
Watch Dr David Lewis of University Hospitals Plymouth NHS Trust describe the mechanism of action of bispecific therapies and detail the key efficacy and safety data from the phase I/II single arm study in patients with highly refractory DLBCL that supports Tepkinly as a treatment option for patients with relapsed or refractory DLBCL after 2 or more lines of systemic therapy.
Integrating Tepkinly into your service – a Consultant Perspective
Tap in to practical pointers from Dr David Tucker of the Royal Cornwall Hospital NHS Trust, Truro, a haematologist with extensive experience with bispecific therapies. Learn how education and enthusiasm, together with planning, could support integration of Tepkinly into your DLBCL service.
Integrating Tepkinly into your service – CNS & Pharmacist Perspectives
Listen to haematology research nurse specialist Nicola Crosbie (Plymouth) and lead haematology pharmacist Vaishali Dulobdas (Birmingham) provide their learnings from integrating Tepkinly into their services. They emphasise the importance of planning, preparedness and providing education for both HCPs and patients.
Tepkinly in practice: a guide to using Tepkinly
Learn from Dr Kim Linton of the Christie in Manchester – one of the principal investigators involved in the pivotal phase I/II single arm study of Tepkinly as a treatment for patients with relapsed or refractory DLBCL after 2 or more lines of systemic therapy – and her experiences using this subcutaneous bispecific antibody in practice.
Abbreviations
CNS=clinical nurse specialist; R/R=relapsed/refractory.
References
- Tepkinly Summary of Product Characteristics.
UK-EPCOR-240322. Date of preparation: September 2024.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
